Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vogt, L.
Right arrow Articles by Navis, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vogt, L.
Right arrow Articles by Navis, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2004) 19: 5-8
© ERA–EDTA 2003; all rights reserved

Editorial Comment

Lipid management in the proteinuric patient: do not overlook the importance of proteinuria reduction

Liffert Vogt1, Gozewijn D. Laverman1, Robin P. F. Dullaart2 and Gerjan Navis1

Department of Internal Medicine, 1Division of Nephrology and 2Division of Endocrinology, University Medical Center Groningen, Groningen, The Netherlands

Correspondence and offprint requests to: Liffert Vogt, MD, Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Email: l.vogt@int.azg.nl

Keywords: chronic renal failure; lipids; proteinuria; statins; renoprotection

The first 150 words of the full text of this article appear below.



   Introduction
 
The markedly elevated cardiovascular risk observed in renal patients is increasingly recognized as an important treatment target [1]. Among the renal populations, proteinuric patients are at particularly high risk, as apparent from the observation of an almost 6-fold increased incidence of myocardial infarction in such patients [2]. Moreover, proteinuria has been shown to be an independent risk factor for cardiovascular morbidity and mortality [3,4]. Most likely, proteinuria-associated lipid abnormalities play a main role in the high cardiovascular risk in proteinuric patients, and thus provide an important treatment target.

Several studies have underlined the efficacy of statins, not only to improve the lipid profile, but also to reduce cardiovascular morbidity and mortality in hyperlipidaemic and hypertensive populations [5,6], and recent post-hoc data from the CARE study showed that statin treatment reduces cardiovascular morbidity in subjects with chronic renal insufficiency . . . [Full Text of this Article]



   Plasma lipoproteins in proteinuria
 


   Effects of symptomatic antiproteinuric treatment on plasma lipoproteins
 


   Effects of lipid lowering drugs in proteinuric patients
 


   Renoprotective effects of statins in proteinuric conditions
 


   Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
L. Vogt, G. D. Laverman, A. van Tol, A. K. Groen, G. Navis, and R. P. F. Dullaart
Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment
Nephrol. Dial. Transplant., January 1, 2006; 21(1): 101 - 106.
[Abstract] [Full Text] [PDF]